Also known as: Viridian Therapeutics
Viridian Therapeutics is a biotechnology company developing treatments for serious and rare diseases, with a focus on thyroid eye disease and related autoimmune indications. Its pipeline includes IGF-1R-targeted candidates and other immunology assets.
Viridian Therapeutics reported positive Phase 3 results for elegrobart in thyroid eye disease, showing significant proptosis reduction and diplopia resolution. The company plans a BLA submission in Q1 2027 and has another IGF-1R inhibitor, veligrotug, under FDA Priority Review with a June 2026 decision date.
Korsana Biosciences launched from stealth with $175 million in funding to advance KRSA-028, a monoclonal antibody targeting amyloid beta plaques in Alzheimer's disease using a blood-brain barrier shuttle technology.
